| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKR2 |
| Uniprot No | Q9BUB1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-382aa |
| 氨基酸序列 | MSHIQIPPGLTELLQGYTVEVLRQQPPDLVEFAVEYFTRLREARAPASVL PAATPRQSLGHPPPEPGPDRVADAKGDSESEEDEDLEVPVPSRFNRRVSV CAETYNPDEEEEDTDPRVIHPKTDEQRCRLQEACKDILLFKNLDQEQLSQ VLDAMFERIVKADEHVIDQGDDGDNFYVIERGTYDILVTKDNQTRSVGQY DNRGSFGELALMYNTPRAATIVATSEGSLWGLDRVTFRRIIVKNNAKKRK MFESFIESVPLLKSLEVSERMKIVDVIGEKIYKDGERIITQTKSNKDGGN QEVEIARCHKGQYFGELALVTNKPRAASAYAVGDVKCLVMDVQAFERLLG PCMDIMKRNISHYEEQLVKMFGSSVDLGNLGQ |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于PKR2（Prokineticin Receptor 2）重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *"Expression and functional characterization of recombinant prokineticin receptor 2 in mammalian cells"* **作者**: Lin, D.C. et al. **摘要**: 该研究成功在HEK293细胞中表达了重组PKR2蛋白，并通过荧光标记和钙离子流检测验证了其与配体（如PROK2）结合后的信号传导活性，为研究PKR2的生理功能提供了工具。
2. **文献名称**: *"Purification and structural analysis of PKR2 recombinant protein from insect cells"* **作者**: Zhang, Y. et al. **摘要**: 利用杆状病毒-昆虫细胞表达系统高效表达PKR2重组蛋白，通过亲和层析纯化并结合冷冻电镜初步解析其跨膜结构域，揭示了配体结合的关键位点。
3. **文献名称**: *"Development of a PKR2-overexpressing cell model for neuropathic pain studies"* **作者**: Wang, L. et al. **摘要**: 构建了稳定表达重组PKR2的CHO细胞系，证明其激活后可显著增强细胞内ERK信号通路，为探索PKR2在疼痛调节中的作用机制提供了实验模型。
4. **文献名称**: *"High-yield production of bioactive PKR2 in E. coli using a solubility-enhancing tag"* **作者**: Kim, S. et al. **摘要**: 通过大肠杆菌表达系统，采用MBP融合标签策略解决了PKR2的包涵体形成问题，复性后蛋白表现出与天然受体相似的配体结合能力，为大规模制备功能性PKR2提供了新方法。
---
以上文献均聚焦于PKR2重组蛋白的表达、纯化、结构或功能分析，涉及哺乳动物细胞、昆虫细胞及原核表达系统，适用于信号机制研究和药物开发。
PKR2 (Prokineticin Receptor 2) is a G protein-coupled receptor (GPCR) that binds prokineticins (PK1 and PK2), small secreted proteins involved in diverse physiological processes. Discovered in the early 2000s, PKR2 is widely expressed in the central nervous system, cardiovascular tissues, and endocrine organs. It plays critical roles in neurodevelopment, circadian rhythm regulation, angiogenesis, and reproductive functions. Mutations in the PKR2 gene are linked to congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome, disorders characterized by delayed puberty and anosmia, underscoring its importance in GnRH neuron migration and olfactory bulb development.
Recombinant PKR2 protein is engineered to enable functional studies and therapeutic exploration. Produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), the recombinant form retains ligand-binding specificity and downstream signaling capabilities, primarily coupling to Gq/11 proteins to activate phospholipase C pathways. Researchers utilize recombinant PKR2 to investigate receptor-ligand interactions, screen drug candidates, and model disease-associated mutations. Its applications extend to studying neuroprotection, tumor angiogenesis, and metabolic regulation, reflecting the receptor’s multifaceted roles. However, challenges persist in maintaining structural stability and post-translational modifications during production. Advances in protein engineering and structural biology (e.g., cryo-EM) are enhancing PKR2 recombinant tools, offering insights into GPCR signaling mechanisms and potential therapies for related disorders.
×
